You think in therapeutic landscapes, not single trials. ClinicaLister ties therapeutic-area trends, biosimilar pipelines, and competitor focus into one cross-filterable view — and connects the ClinicaLister app to your AI assistant, so the briefing your MSL team stands behind comes with its citations already attached.
The highest-leverage things ClinicaLister does for a medical affairs lead.
Every recurring activity, mapped to what ClinicaLister does — on which surface (the App, the MCP graph, or both), the time it saves, and how confident that claim is.
| Activity | What ClinicaLister does | Surface | Time saved | Confidence |
|---|---|---|---|---|
| TA landscape monitoring | Therapeutic-area and condition charts cross-filter to phase, sponsor, and condition in one interactive view. | App | weekly spreadsheet → a glance | High |
| Biosimilar / LoE tracking | Approved biosimilars, interchangeability status, and loss-of-exclusivity urgency sit on every drug profile. | App | manual Purple Book / EMA removed | High |
| Safety-signal surveillance | Disproportionality signals and a severity-ranked adverse-event dashboard give a standing safety view per drug. | Both | standing view — candidates, not causal | High |
| Competitor focus by indication | A pipeline competitive matrix with sponsor drill-down shows who is active in each indication. | App | instant "who's active where" | High |
| MSL pre-call / KOL-meeting prep | Filter by indication and geography to pull drug-linked trials and their investigator contacts in one step. | Both | ~2h → minutes (illustrative) | Medium |
| Investigator / KOL mapping by territory | An investigator directory and site-overlap map turn trial contacts into a territory-ready list. | Both | territory list without scraping | Medium |
| Endpoint / trial-design comparison | Your AI assistant compares endpoints and trial designs side by side instead of reading protocols one at a time. | MCP | side-by-side vs reading protocols | Medium |
| Publication / evidence-gap tracking | Your AI assistant maps the publication landscape, journal impact, and evidence gaps around a trial or drug. | MCP | structured map vs PubMed triage | Medium |
| Label / safety context for the field | A safety-profile briefing pulls the official label and adverse-event summary into one field-ready pull per drug. | MCP | one pull per drug | High |
| Molecule / MoA scouting | Your AI assistant surfaces emerging molecules, their diseases, and the surrounding landscape so new classes don't slip past. | MCP | emerging classes without manual research | Medium |
| Competitor-change awareness | Field-level change detection flags competitor moves across every monitored trial field the same day they happen. | App | landscape moves in hours | Medium |
| Congress / medical-strategy briefing inputs | Therapeutic-area charts, the competitive matrix, and publications compile into decision-ready, source-cited briefings. | Both | decision-ready, sourced briefings | Medium |
Straight answers on where ClinicaLister stops today — so there are no surprises.
Therapeutic area and phase both filter the same view, but not yet as a single cross-tab snapshot — you pivot between them rather than seeing both axes at once.
Safety signals are statistical candidates for review, not confirmed findings — a landscape-awareness view, not a pharmacovigilance or signal-management system.
Registered and published activity only — programs that are early, undisclosed, or unpublished will lag the very earliest signals.
No MSL CRM or field-interaction layer — it supplies the landscape and contact data, but not KOL engagement history, call notes, or territory-plan management.
No internal medical content — it does not handle medical-information requests, approved responses, insight capture, or advisory-board materials.
See the whole therapeutic landscape, not just individual trials — emerging drug classes, biosimilar pipelines, safety signals, and exactly where competitors are focusing, all in one place.